Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT

User menu

Search

  • Advanced search
eNeuro

eNeuro

Advanced Search

 

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT
PreviousNext
Research ArticleNew Research, Disorders of the Nervous System

Inhibiting Bone Morphogenetic Protein 4 Type I Receptor Signaling Promotes Remyelination by Potentiating Oligodendrocyte Differentiation

Alistair E. Govier-Cole, Rhiannon J. Wood, Jessica L. Fletcher, David G. Gonsalvez, Daniel Merlo, Holly S. Cate, Simon S. Murray and Junhua Xiao
eNeuro 26 April 2019, 6 (2) ENEURO.0399-18.2019; DOI: https://doi.org/10.1523/ENEURO.0399-18.2019
Alistair E. Govier-Cole
Department of Anatomy and Neuroscience, University of Melbourne, Parkville 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alistair E. Govier-Cole
Rhiannon J. Wood
Department of Anatomy and Neuroscience, University of Melbourne, Parkville 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica L. Fletcher
Department of Anatomy and Neuroscience, University of Melbourne, Parkville 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jessica L. Fletcher
David G. Gonsalvez
Department of Anatomy and Neuroscience, University of Melbourne, Parkville 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Merlo
Department of Anatomy and Neuroscience, University of Melbourne, Parkville 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly S. Cate
Department of Anatomy and Neuroscience, University of Melbourne, Parkville 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon S. Murray
Department of Anatomy and Neuroscience, University of Melbourne, Parkville 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Simon S. Murray
Junhua Xiao
Department of Anatomy and Neuroscience, University of Melbourne, Parkville 3010, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Junhua Xiao
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Inhibiting BMP4/BMPRI signaling following demyelination promotes remyelination in vivo. A, Representative MBP IHC images showing myelin protein in the caudal corpus callosi of healthy control (control) and 5 week cuprizone-challenged mice (Cuprizone 5w, top panels); and 5 week cuprizone-challenged mice followed by 1 week of recovery with vehicle (Vehicle recovery) or LDN-193189 (LDN recovery) infusion (bottom panels). B, Quantification of integrated density of MBP immunostaining. No significant differences were observed between control and cuprizone-fed mice, or between vehicle- and LDN-infused mice. C, Representative SCoRe images to identify myelin in the caudal corpus callosi of healthy control (control) and 5 week cuprizone-challenged mice (Cuprizone (5w), top panels); and 5 week cuprizone-challenged mice followed by 1 week of recovery with vehicle (Vehicle recovery) or LDN-193189 (LDN recovery) infusion (bottom panels). D, Quantification of myelinated area (SCoRe signal that is pixelated) as a percentage of the total area measured. The SCoRe signal is significantly reduced in 5 week cuprizone-challenged mice [Cuprizone (5w) compared with healthy control (Ctrl) mice, confirming demyelination (B)]. LDN-193189-infused mice display a significantly greater SCoRe signal than the vehicle-infused control group (C), indicating greater remyelination. E, TEM cross-sectional images of caudal corpus callosum axons of 5 week cuprizone-challenged mice followed by 1 week of recovery with vehicle (Vehicle recovery) or LDN-193189 (LDN recovery) infusion. F, A scatterplot comparison of g-ratio distribution relative to axonal diameter. LDN-infused mice had a significantly higher average g-ratio than vehicle-infused controls (p = 0.016). G, Proportion of total myelinated axons in the caudal corpus callosum of vehicle- and LDN-infused mice following 5 weeks of cuprizone administration. A trend, but a nonsignificant increase, was observed in LDN-infused mice compared with vehicle controls. H, The average g-ratio of axons in the caudal corpus callosum of vehicle- and LDN-infused mice following 5 weeks of cuprizone treatment. Mice treated with LDN-193189 after 5 weeks of cuprizone had more thinly myelinated axons (high g-ratio) in the corpus callosum compared with vehicle-infused mice. I, Number of axons in the corresponding g-ratio range for vehicle- versus LDN-infused mice following 5 weeks of cuprizone treatment. EM analysis indicated a higher number of axons with thinner myelin in the LDN-treated group, indicating greater remyelination (N = 4-6 animals/group for SCoRe; N = 3 animals/group for EM). *p < 0.05, ****p < 0.0001. Scale bars: SCoRe images, 50 µm; TEM images, 2 µm.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Inhibiting BMP4/BMPRI signaling following demyelination promotes oligodendrocyte differentiation in vivo. A, Representative micrographs of immunostaining in the caudal corpus callosi of healthy control mice (control), mice subjected to 5 weeks of cuprizone treatment (Cuprizone 5w), and mice subjected to 5 weeks of cuprizone with either vehicle (Vehicle recovery) or LDN-193189 (LDN recovery) infusion for 1 week, and immunostained with OLIG2 and either PDGFRα or CC1. B, C, Analysis of OLIG2+ cell number in healthy control mice (control), mice subjected to 5 weeks of cuprizone treatment (Cuprizone 5w), and mice infused with either vehicle (Vehicle recovery) for 1 week or LDN-193189 (LDN recovery) for 1 week. As expected, the total number of OLIG2+ cells is significantly decreased after 5 weeks of cuprizone treatment compared with controls. D, Quantification of the proportion of OLIG2+/CC1+ mature oligodendrocytes showing a significant reduction at the end of cuprizone feeding. E, LDN-193189-infused mice have a significantly higher proportion of mature oligodendrocytes compared with the vehicle control group following 1 week recovery. F, Quantification of the proportion of OLIG2+/PDGFRα+ OPCs showing a significant increase at the end of cuprizone feeding. G, LDN-193189-infused mice have a significantly smaller fraction of OPCs compared with the vehicle control group following recovery (N = 4-6 animals/group). *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar, 50 µm.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Inhibiting BMP4/BMPRI signaling exerts no influence on astrocytes or microglia in vivo. A, B, Representative micrographs of immunostaining in the caudal corpus callosi of healthy control mice (control), mice subjected to 5 weeks of cuprizone treatment (Cuprizone 5w), and mice subjected to 5 weeks of cuprizone treatment with either vehicle (Vehicle recovery) or LDN-193189 (LDN recovery) infusion for 1 week, and immunostained with GFAP (A) or IBA-1 (B). C, Quantification of the integrated density of GFAP immunofluorescence. There is no significant change in GFAP immunofluorescence at peak demyelination (Cuprizone 5w; left) or following the infusion of LDN-193189 (LDN recovery) for 1 week compared with control groups (Control, Vehicle; right panel). D, Quantification of the integrated density of IBA-1 immunofluorescence. There is a significant increase in IBA-1 immunofluorescence in the corpus callosum at peak demyelination (Cuprizone 5w; left); however, there is no significantly different increase in IBA-1 immunofluorescence between vehicle (Vehicle recovery) or LDN-193189 (LDN recovery) infusion during 1 week of recovery after cuprizone treatment (right; N = 4-6 animals/group). ****p < 0.0001. Scale bar, 50 µm.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    BMP4 signals via BMPR1 in OPCs to enhance oligodendrocyte differentiation and reduce astrogliogenesis in vitro. A, Representative micrographs of immunostaining of differentiated OPC cultures for MBP and GFAP under untreated (Control) conditions, or following treatment with BMP4, LDN-193189 (LDN), or both BMP4 and LDN-193189 (LDN+BMP4). B, Quantification of cell phenotypic distribution for each condition based on GFAP expression and MBP+ morphology. MBP+ cells were classified as either mature (flattening of branched extracellular membrane) or immature (branched morphology but not fused layers). C, Quantification of the proportion of GFAP+ cells in the cultures. BMP4 significantly increased the proportion of GFAP+ cells compared with untreated (Control) cultures. While LDN-193189 (LDN) alone exerted no significant effect, pretreatment with LDN before BMP4 (LDN+BMP4) significantly abrogated effect of BMP4 on astrocytes. D, Quantification of the proportion of immature oligodendrocytes in the cultures. Treatment with BMP4 or LDN-193189 (LDN) exerted no significant effect, whereas pretreatment with LDN-193189 before BMP4 (LDN+BMP4) significantly increased the proportion of immature oligodendrocytes. E, Quantification of the proportion of mature oligodendrocytes in the cultures. Treatment with BMP4 significantly blocked OPC differentiation, whereas LDN-193189 (LDN) alone exerted no significant effect. Pretreatment with LDN before BMP4 (LDN+BMP4) significantly abrogated the effect of BMP4 on oligodendrocyte differentiation (N = 4 animals/group). ****p < 0.0001. Scale bar, 20 µm.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    BMP4 signals via BMPR1 in OPCs to promote myelin formation in vitro. A, Representative micrographs of myelinating DRG/OPC cocultures treated with vehicle (control), BMP4, LDN-193189 (LDN), or both LDN-193189 and BMP4 (LDN+BMP4) for 14 d and immunostained for MBP and Neurofilament. Arrows indicate MBP+ myelin segments colabeled with NFL+ axons. B, Quantification of the number of MBP+ myelinated axonal segments per field from these cocultures. BMP4 treatment significantly reduced the number of MBP+ myelin segments compared with cocultures, which is blocked by the pretreatment of LDN-193189 (LDN+BMP4; N = 4 independent cocultures/group). *p < 0.05, ****p < 0.0001. Scale bar, 30 µm.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Inhibiting BMP4/BMPRI signaling in OPCs alters the expression of transcription factor Id4 and Gfap, but not Mbp or Myrf. A, B, qRT-PCR analysis of Id4 and Gfap transcript levels from OPCs cultured in differentiation media and treated with LDN-193189, BMP4, or both, or vehicle (control) over various time points. *BMP4 significantly increased the level of Id4 transcripts at 2 and 24 h compared with the control, and this upregulation is blocked by pretreatment with LDN-193189 before BMP4 exposure. *Gfap expression was also significantly reduced by pretreatment of OPCs with LDN-193189 before BMP4 exposure. C, D, qRT-PCR analysis of myelin protein gene Mbp and key myelination transcription factor Myrf from OPCs treated with LDN-193189, BMP4, or both, or vehicle over 24 h. BMP4 significantly reduced the expression level of both Mbp and Myrf genes, with this effect reduced by LDN-193189 pretreatment; N = 3 independent cultures/group). *p < 0.05, **p < 0.01.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    BMP4 signals via BMPR1A in OPCs to potentiate oligodendrocyte differentiation and reduce astrogliogenesis in vitro. A, Representative micrographs of immunostaining of differentiated OPC cultures (isolated from Pdgfra-CreERT2::Bmpr1a fl/fl mice) for MBP and GFAP under untreated (Control) conditions, or following treatment with BMP4, 4OHT, or both BMP4 and 4OHT (+4OHT+BMP4). B, Quantification of cell-phenotypic distribution for each condition based on GFAP expression and MBP+ morphology, as described above (Fig. 4B). C, Quantification of the proportion of GFAP+ cells in the cultures. BMP4 significantly increased the proportion of GFAP+ cells compared with untreated (Control) cultures, whereas 4OHT alone exerted no significant effect. Pretreatment with 4OHT before BMP4 (+4OHT+BMP4) significantly attenuated the effect of BMP4. D, Quantification of the proportion of immature oligodendrocytes in the cultures. Treatment with BMP4, 4OHT, or both BMP4 and 4OHT (+4OHT+BMP4) exerted no significant effect. E, Quantification of the proportion of mature oligodendrocytes in the cultures. Treatment with BMP4 significantly decreased OPC differentiation, whereas 4OHT alone exerted no significant effect. Pretreatment with 4OHT before BMP4 (+4OHT+BMP4) significantly attenuated the inhibitory effect of BMP4 on OPC differentiation. F, PCR analysis of 4OHT-treated OPCs to assess Bmpr1a knockout. Pdgfra-CreERT2::Bmpr1a fl/fl and Cre[−] OPCs were isolated and treated with 4OHT for 24 h and analyzed for the transcription of a sequence corresponding to Bmpr1a-ex2, rendering the resulting protein untranscribable; N = 4 animals/group). *p < 0.05, ****p < 0.0001. Scale bar, 20 µm.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    BMP4 signals via BMPR1A in OPCs to promote myelination in vitro. A, Representative micrographs of immunostaining for MBP and Neurofilament (NFL) in myelinating cocultures containing OPCs isolated from Pdgfra-CreERT2::Bmpr1a fl/fl mice. The cocultures were treated with or without 4OHT for 24 h before 14 d of myelination. Arrows indicate MBP+ myelinated axons segments colabeled with NFL+ axons. B, Quantification of MBP+ myelinated axonal segments from these cocultures. 4OHT-induced BMPRIA ablation in OPCs causes significantly more MBP+ myelinated axonal segments compared with controls. C, Western blot analysis of BMPRIA and myelin proteins (MOG and MBP) in sister cocultures from A and B, treated with either 4OHT or vehicle. Treatment with 4OHT substantially reduced BMPRIA expression and leads to qualitatively more myelin proteins (MBP and MOG) expression compared with controls. D, Representative micrographs of immunostaining for MBP and NFL in myelinating cocultures containing OPCs isolated from Bmpr1a fl/fl (Cre− control) mice. The cocultures were treated with or without 4OHT for 24 h before 14 d of myelination. Arrows indicate MBP+ myelin segments colabeled with NFL+ axons. E, Quantification of MBP+ myelinated axonal segments from cocultures. Treatment with 4OHT did not exert a significant effect on myelination in the Cre− cocultures (N = 3 independent cultures/treatment group). **p < 0.01. Scale bar, 30 µm.

Tables

  • Figures
    • View popup
    Table 1:

    Primer sequences used for qRT-PCR

    Gene nameForward primerReverse primer
    18S5´CGAACGTCTGCCCTATCAACTT3´5’ACCCGTGGTCACCATGGTA3’
    Myelin basic protein (Mbp)5´CCCGTGGAGCCGTGATC3´5´TCTTCAAACGAAAAGGGACGAA-3′
    Glial fibrillary acidic protein (Gfap)5´CGTTTCTCCTTGTCTCGAATGA3´5´CCCGGCCAGGGAGAAGT3´
    Inhibitor of DNA binding (Id4)5´TTTGCACGTTCACGAGCATT3´5´GCGGTCATAAAAGAAGAAACGAA3´
    Myelin regulatory factor (Myrf)5′AAGGAGCTGCCTATGCTCACCT3′5′GCCTCTAGCTTCACACCATGCA3′
    BMPRIA (Bmpr1a)5´TCATGTTCAAGGGCAGAATCTAGA3´5´GGCAAGGTATCCTCTGGTGCTA3´
    BMPRIB (Bmpr1b)5´GCGCACCCCGATGTTG3´5´CATGTCCCCTAAGAAGCTTTCTG3´
    BMPRIA-ex25´GTTCATCATTTCTCATGTTCAAACTA3´5´AATCAGAGCCTTCATACTTCATACACC3´
    • View popup
    Table 2:

    Statistics

    Test identifierType of testSample sizeConfidence intervals
    a0Student’s unpaired two-tailed t testThree animals per treatment; six technical replicates per animal−11.1 to 37.1
    aStudent’s unpaired two-tailed t testFour control and cuprizone-fed animals, six for vehicle- and LDN-treated animals; three technical replicates per animal14.81–55.60
    bStudent’s unpaired two-tailed t testFour control and cuprizone-fed animals, six for vehicle- and LDN-treated animals; three technical replicates per animal−20.02 to −2.95
    b1Student’s unpaired two-tailed t testFour vehicle- and five LDN-treated animals; six technical replicates per animal, approximately 100 axons counted per animal−45.96 to 11.67
    b2Student’s unpaired two-tailed t testThree vehicle- and three LDN-treated animals; six technical replicates per animal, approximately 100 axons counted per animal0.017–0.091
    b3Two-way ordinary ANOVA with Tukey’s multiple corrections testThree vehicle- and three LDN-treated animals; six technical replicates per animal, approximately 100 axons counted per animal−23.39 to −0.6092
    b4Student’s unpaired two-tailed t testFour control and cuprizone-fed animals, six for vehicle- and LDN-treated animals; three technical replicates per animal0.76–123.91
    b5Student’s unpaired two-tailed t testFour control and cuprizone-fed animals, six for vehicle- and LDN-treated animals; three technical replicates per animal−81.21 to 26.21
    cStudent’s unpaired two-tailed t testFour control and cuprizone-fed animals, six for vehicle- and LDN-treated animals; three technical replicates per animal−94.40 to −60.46
    dStudent’s unpaired two-tailed t testFour control and cuprizone-fed animals, six for vehicle- and LDN-treated animals; three technical replicates per animal38.05–91.35
    eStudent’s unpaired two-tailed t testFour control and cuprizone-fed animals, six for vehicle- and LDN-treated animals; three technical replicates per animal4.59–17.66
    fStudent’s unpaired two-tailed t testFour control and cuprizone-fed animals, six for vehicle- and LDN-treated animals; three technical replicates per animal−9.19 to −1.36
    gStudent’s unpaired two-tailed t testFour control and cuprizone-fed animals, six for vehicle- and LDN-treated animals; three technical replicates per animal−4980.00 to 2499.00
    hStudent’s unpaired two-tailed t testFour control and cuprizone-fed animals, six for vehicle- and LDN-treated animals; three technical replicates per animal−33,305.00 to −21,828.00
    IStudent’s unpaired two-tailed t testFour control and cuprizone-fed animals, six for vehicle- and LDN-treated animals; three technical replicates per animal−7695.00 to 2665.00
    jTwo-way ordinary ANOVA with Tukey’s multiple corrections testFour independent cultures; three technical replicates per treatment; approximately 500–600 cells counted per treatment−81.20 to −66.60
    kTwo-way ordinary ANOVA with Tukey’s multiple corrections testFour independent cultures; three technical replicates per treatment; approximately 500–600 cells counted per treatment−68.00 to −53.30
    lTwo-way ordinary ANOVA with Tukey’s multiple corrections testFour independent cultures; three technical replicates per treatment; approximately 500–600 cells counted per treatment−23.10 to −8.46
    mOne-way ordinary ANOVA with Tukey’s multiple corrections testThree independent cultures; eight 10× image fields counted per treatment group19.43–51.24
    nOne-way ordinary ANOVA with Tukey’s multiple corrections testThree independent cultures; eight 10× image fields counted per treatment group−51.15 to −19.35
    oOne-way ordinary ANOVA with Tukey’s multiple corrections testThree independent cultures; eight 10× image fields counted per treatment group.−33.99 to −2.18
    pOne-way ordinary ANOVA with Tukey’s multiple corrections testThree independent cultures; three technical replicates per treatment−5.49 to −2.99
    qOne-way ordinary ANOVA with Tukey’s multiple corrections testThree independent cultures; three technical replicates per treatment−7.02 to −3.91
    rOne-way ordinary ANOVA with Tukey’s multiple corrections testThree independent cultures; three technical replicates per treatment1.11–3.61
    sOne-way ordinary ANOVA with Tukey’s multiple corrections testThree independent cultures; three technical replicates per treatment2.84–5.95
    tOne-way ordinary ANOVA with Tukey’s multiple corrections testThree independent cultures; three technical replicates per treatment−2.77 to −0.35
    uOne-way ordinary ANOVA with Tukey’s multiple corrections testThree independent cultures; three technical replicates per treatment.−0.17 to 2.25
    vOne-way ordinary ANOVA with Tukey’s multiple corrections testThree independent cultures; three technical replicates per treatment−1.36 to −0.16
    wOne-way ordinary ANOVA with Tukey’s multiple corrections testThree independent cultures; three technical replicates per treatment−2.47 to −0.51
    xStudent’s unpaired two-tailed t testThree independent cultures; three technical replicates per treatmentNot available
    yTwo-way ordinary ANOVA with Tukey’s multiple corrections testThree independent cultures; three technical replicates per treatment; approximately 500–600 cells counted per treatment−89.42 to −43.00
    zTwo-way ordinary ANOVA with Tukey’s multiple corrections testThree independent cultures; three technical replicates per treatment; approximately 500–600 cells counted per treatment−32.21 to 14.20
    aaTwo-way ordinary ANOVA with Tukey’s multiple corrections testFour independent cultures; three technical replicates per treatment; approximately 500–600 cells counted per treatment−23.20 to 23.30
    abTwo-way ordinary ANOVA with Tukey’s multiple corrections testFour independent cultures; three technical replicates per treatment; approximately 500–600 cells counted per treatment−19.65 to −2.29
    acTwo-way ordinary ANOVA with Tukey’s multiple corrections testFour independent cultures; three technical replicates per treatment; approximately 500–600 cells counted per treatment13.07–30.42
    adStudent’s unpaired two-tailed t testThree independent cultures for both Pdgfra-CreERT2::Bmpr1afl/fl and Bmpr1afl/fl cocultures; eight 10× image fields counted per treatment group14.65–70.88
    aeStudent’s unpaired two-tailed t testThree independent cultures for both PdgfraCreERT2::Bmpr1afl/fl and Bmpr1afl/fl cocultures; eight 10x image fields counted per treatment group−39.73 to 36.81
    • View popup
    Table 3:

    Summary of differentially regulated BMP/TGF-β signaling pathway genes in OPCs cultured in LDN-193189, BMP4, or both, or vehicle for 24 h in differentiating conditions

    Up/downFold regulationp value
    BMP4 vs control
    Gene name
    Epithelial membrane protein 1 (Emp1)↑9.19 *
    Noggin (Nog)↑6.20***
    Growth arrest and DNA-damage-inducible 45 β (Gadd45b)↑5.17 *
    Cyclin-dependent kinase inhibitor 1A (Cdkn1a)↑5.11**
    Transforming growth factor, beta 3 (Tgfb3)↑4.37 *
    Jun-B oncogene (Junb)↑4.27 *
    Latent transforming growth factor beta binding protein 1 (Ltbp1)↑3.94**
    BMP and activin membrane-bound inhibitor (Bambi)↑3.84**
    BMP-binding endothelial regulator (Bmper)↑3.40**
    Inhibitor of DNA binding 2 (Id2)↑2.25 *
    Distal-less homeobox 2 (Dlx2)↑2.10 *
    TGFβ-1-induced transcript (Tgfb1i1)↑2.06 *
    Inhibitor of DNA binding 1 (Id1)↑1.94 *
    FBJ osteosarcoma oncogene (Fos)↑1.94**
    SRY-box containing gene 4 (Sox4)↑1.87 *
    Small MAD homolog 1 (Smad1)↑1.50 *
    BMP receptor 1A (Bmpr1a)↑1.54 *
    Small MAD homolog 5 (Smad5)↓−1.27 *
    Signal transducer and activator of transcription (Stat1)↓−1.35 *
    TGF-β receptor I (Tgfbr1)↓−1.60 *
    Small MAD homolog 2 (Smad2)↓−1.66**
    Small MAD homolog 7 (Smad7)↓−1.74 *
    SMAD specific E3 ubiquitin protein ligase 1 (Smurf1)↓−2.13****
    Plasminogen activator, urokinase (Plau)↓−5.16**
    Bone morphogenetic protein 4 (Bmp4)↓−5.53 *
    LDN-193189 vs controla
    Gene name
    Epithelial membrane protein 1 (Emp1)↓−2.07 *
    Inhibitor of DNA binding 2 (Id2)↓−3.15**
    BMP-binding endothelial regulator (Bmper)↓−3.63**
    Inhibitor of DNA binding 1 (Id1)↓−3.65 *
    Noggin (Nog)↓−6.35 *
    MDS1 and EVI1 complex locus (Mecom)↓−22.15**
    LDN-193189+BMP4 vs BMP4b
    Gene name
    Bone morphogenetic protein 4 (Bmp4)↑3.32 *
    TGF-β receptor I (Tgfbr1)↑1.69 *
    Small MAD homolog 5 (Smad5)↑1.58 *
    Signal transducer and activator of transcription (Stat1)↑1.41 *
    Noggin (Nog)↓−1.36 *
    Distal-less homeobox 2 (Dlx2)↓−1.40 *
    FBJ osteosarcoma oncogene (Fos)↓−1.42 *
    Col1a1↓−1.64 *
    BMP-binding endothelial regulator (Bmper)↓−2.12 *
    BMP and activin membrane-bound inhibitor (Bambi)↓−2.22 *
    Transforming growth factor beta-1-induced transcript 1 (Tgfb1i1)↓−2.50 *
    Cyclin-dependent kinase inhibitor 1A (Cdkn1a)↓−3.23**
    Insulin-like growth factor 1 (Igf1)↓−3.50**
    Jun-B oncogene (Jun)↓−4.19 *
    Latent transforming growth factor beta binding protein 1 (Ltbp1)↓−5.46***
    Epithelial membrane protein 1 (Emp1)↓−9.63 *
    • ↵ aValues are compared with controls.

    • ↵ bValues are compared with BMP4.

    • ↵*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Back to top

In this issue

eneuro: 6 (2)
eNeuro
Vol. 6, Issue 2
March/April 2019
  • Table of Contents
  • Index by author
  • Ed Board (PDF)
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibiting Bone Morphogenetic Protein 4 Type I Receptor Signaling Promotes Remyelination by Potentiating Oligodendrocyte Differentiation
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Inhibiting Bone Morphogenetic Protein 4 Type I Receptor Signaling Promotes Remyelination by Potentiating Oligodendrocyte Differentiation
Alistair E. Govier-Cole, Rhiannon J. Wood, Jessica L. Fletcher, David G. Gonsalvez, Daniel Merlo, Holly S. Cate, Simon S. Murray, Junhua Xiao
eNeuro 26 April 2019, 6 (2) ENEURO.0399-18.2019; DOI: 10.1523/ENEURO.0399-18.2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Inhibiting Bone Morphogenetic Protein 4 Type I Receptor Signaling Promotes Remyelination by Potentiating Oligodendrocyte Differentiation
Alistair E. Govier-Cole, Rhiannon J. Wood, Jessica L. Fletcher, David G. Gonsalvez, Daniel Merlo, Holly S. Cate, Simon S. Murray, Junhua Xiao
eNeuro 26 April 2019, 6 (2) ENEURO.0399-18.2019; DOI: 10.1523/ENEURO.0399-18.2019
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • Significance Statement
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
    • Synthesis
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • BMP4
  • BMPRIA
  • demyelination
  • oligodendrocyte

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

New Research

  • Postnatal development of projections of the postrhinal cortex to the entorhinal cortex in the rat
  • Visual System Hyperexcitability and Compromised V1 Receptive Field Properties in Early-Stage Retinitis Pigmentosa in Mice
  • Enhancement of motor cortical gamma oscillations and sniffing activity by medial forebrain bundle stimulation precedes locomotion
Show more New Research

Disorders of the Nervous System

  • NEURONAL CORRELATES OF HYPERALGESIA AND SOMATIC SIGNS OF HEROIN WITHDRAWAL IN MALE AND FEMALE MICE
  • Visual System Hyperexcitability and Compromised V1 Receptive Field Properties in Early-Stage Retinitis Pigmentosa in Mice
  • Robust, long-term video EEG monitoring in a porcine model of post-traumatic epilepsy
Show more Disorders of the Nervous System

Subjects

  • Disorders of the Nervous System

  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Latest Articles
  • Issue Archive
  • Blog
  • Browse by Topic

Information

  • For Authors
  • For the Media

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2022 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.